DMMS.EDU

DMMS.EDU (Diabetes Mellitus Metabolic Simulator for Education), developed by The Epsilon Group (TEG), is a simulation environment designed to demonstrate glucose response in people with Type 1, Type 2, or pre-diabetes mellitus. It hosts over 50 virtual subjects who can be treated with combinations of diet, exercise, and medication, making it suited for examining the impact of treatment and lifestyle choices on glucose control.

The tool is intended for diabetes education, allowing clinicians, educators, and patients to visualise how various interventions affect blood glucose levels. Subject parameters — including insulin blood levels and insulin sensitivities — are derived from clinical studies (Dalla Man 2007), while lifestyle models draw on human studies covering exercise, mixed meals, and circadian rhythm. Medication models are based on pharmacokinetic/pharmacodynamic data for drugs including long-acting and rapid-acting insulin and metformin.

Educational and Clinical Use Cases

• Illustrating the relationship between carbohydrate intake at meals and blood glucose changes throughout the day, supporting understanding of post-prandial hyperglycemia.
• Comparing a current treatment plan against a proposed plan that includes adjusted diet and exercise, to evaluate potential improvements in blood glucose variability and HbA1c levels.
• Comparing glucose control under insulin treatment versus oral medication for subjects who may benefit from transitioning to insulin.
• Demonstrating the relationship between meals, exercise, and the potential for hypoglycemia during the daytime or at night.
• Showing the results of not managing daily lifestyle habits versus glucose control achieved through improved self-management and optimised treatment adjustments.

Subject Populations

• DMMS.EDU is provided with in silico subject populations representing the variability found in real-world populations.
• Cohorts cover Type 1, Type 2, and prediabetic conditions.
• Subject selection can be matched to best reflect individual patient parameters.

Software Features

• User-friendly, intuitive input and data display with tool-tip support.
• Support for Type 1, Type 2, and prediabetic conditions within a single compact format.
• Both graphical and tabular comparison of control versus proposed treatment plans, including signal outputs and derived statistics.
• User-defined simulation duration: a single day or up to three months.
• Support for anti-diabetic drugs with full control over dosing times and quantities.
• Support for both basal insulin (continuous or long-acting) and rapid-acting bolus injections.
• Support for meal boluses and correction boluses, which may be meal-based or alarm-based.
• Meals and exercise patterns — timing and quantity — can be defined for each day of the simulation.
• All results, including signal outputs, comparison graphs, and statistics, can be saved to data files for later reference.
• Treatment plans can be saved to files so simulations can be repeated as-is or with modifications.
• Extensive user manual with repeatable examples.

Validation and Regulatory Support

• TEG offers further validation of in silico study results through simulation services using 100-subject, FDA-accepted virtual populations.
• TEG can provide custom modelling of devices and drugs, and assist in designing clinical protocols to client specifications.
• Simulation results from FDA-accepted virtual populations can be submitted to the FDA as pre-clinical study data for IDE or 510(k) approval of new devices, as preliminary data for IND applications for new drugs, or for assessment of bioequivalence.